Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model

Radiology

Volumn 237, Issue 1, 2005, Pages 151-158

  Kan, Zyxing ^a   Phongkitkaran, Sith ^a   Kobayashi, Satoshi ^a   Tang, Yi ^a   Ellis, Lee M ^a   Lee, Ting Y ^b   Charnsangavej, Chusilp ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; CANCER MODEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DENSITY; FEMALE; LIVER TUMOR; MEASUREMENT; METASTASIS; MOUSE; NONHUMAN; PERFUSION; PERMEABILITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SURFACE PROPERTY; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VALIDATION PROCESS;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; INDOLES; LIVER NEOPLASMS, EXPERIMENTAL; MICROCIRCULATION; PROTEIN KINASE INHIBITORS; PYRROLES; RANDOM ALLOCATION; RATS; RATS, INBRED F344; TOMOGRAPHY, X-RAY COMPUTED;

EID: 25144450545     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2363041293     Document Type: Article

References (44)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Folkman J. Tumor angiogenesis. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer medicine. Baltimore, Md: Decker, 2000; 132-152.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 suppl 16):15-18.
4. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380.
5. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039.
6. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29(6 suppl 16):3-9.
7. American Cancer Society. Angiogenesis inhibitors in clinical trials, http://www.cancer.gov /clinicaltrials/developments/anti-angio-table. Accessed May 21, 2004.
8. Food and Drug Administration. FDA approves first angiogenesis inhibitor to treat colorectal cancer. FDA News, http://www.fda.gov/bbs/topics/NEWS/2004/ NEW01027.html. Accessed May 21, 2004.
9. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002; 38:1564-1579.
10. Weidner N. Intratumor mocrovessel density as a prognostic factor in cancer. Am J Pathol 1995; 147:9-19.
11. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
12. Fox SB. Tumor angiogenesis and prognosis. Histopathology 1997; 30:294-301.
13. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94:883-893.
14. Lee TY. Functional CT: physiological models. Trends Biotechnol 2002; 20:S3-S10.
15. Miles KA, Griffiths MR. Perfusion CT: a worth-while enhancement? Br J Radiol 2003; 76:220-231.
16. Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000; 7:840-850.
17. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. AJNR Am J Neuroradiol 2000; 21:462-470.
18. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. Dynamic CT measurement of cerebral blood flow: a validation study. AJNR Am J Neuroradiol 1999; 20:63-73.
19. Purdie TG, Henderson E, Lee TY. Functional CT imaging of antiangiogenesis in rabbit VX2 soft-tissue tumor. Phys Med Biol 2001; 46:3161-3175.
20. Swensen SJ, Brown LR, Colby TV, Weaver AL, Midthun DE. Lung nodule enhancement at CT: prospective findings. Radiology 1996; 201:447-455.
21. Platt JF, Francis IR, Ellis JH, Reige KA. Liver metastases: early detection based on abnormal contrast material enhancement at dual-phase helical CT. Radiology 1997; 205:49-53.
22. Miles KA, Leggett DA, Kelley BB, Hayball MP, Sinnatamby R, Bunce I. In vivo assessment of neovascularization of liver metastases using perfusion CT. Br J Radiol 1998; 71:276-281.
23. Neri A, Welch D, Kawaguchi T, Nicolson GL. Development and biological properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J Natl Cancer Inst 1982; 68:507-517.
24. Hamby JM, Showalter HD. Small molecular inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol Ther 1999; 82:169-193.
25. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a small molecule inhibitor of VEGF receptor tyrosine kinase activity, as anti-angiogenesis agent. Anticancer Drug Des 2000; 15:29-41.
26. Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 2000; 6:4848-4858.
27. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59:99-106.
28. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59:5412-5416.
29. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gather KC, Harris AL. Quantification and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995; 177:275-283.
30. McCarty MF, Liu W, Fan F, et al. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med 2003; 9:53-58.
31. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000; 5(suppl 1):11-15.
32. Gradishar WJ. Endpoints for determination of efficacy of antiangiogenic agents in clinical trials. In: Teicher BA, ed. Antiangiogenic agents in cancer therapy. Totowa, NJ: Humana, 1999; 341-354.
33. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13:1055-1066.
34. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125:1591-1598.
35. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003; 162:183-193.
36. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989.
37. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-3736.
38. Kan Z, Kobayashi S, Phongkitkarun S, Charnsangavej C. Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. Radiology 2005; 237:000-000.
39. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockage, hormone ablation, and chemotherapy. Cancer Res 2000;60:4556-4660.
40. [Published correction appears in Cancer Res 2001;61:6304.]
41. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60:5565-5570.
42. Vajkoczy P, Menger MD, Vollmar B, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multifluorescence videomicroscopy. Neoplasia 1999; 1:31-41.
43. Montermini D, Winlove CP, Michel C. Effects of perfusion rate on permeability of frog and rat mesenteric microvessels to sodium fluorescein. J Physiol 2002; 543:959-975.
44. Phongkitkarun S, Kobayashi S, Kan Z, et al. Quantification of angiogenesis by functional computed tomography in a matrigel model in rats. Acad Radiol 2004; 11:573-582.